Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News EKF Diagnostics’ diabetic kidney disease test shows benefits in studies

EKF Diagnostics’ diabetic kidney disease test shows benefits in studies

29th May 2014

EKF Diagnostics has announced the findings of new studies validating its early-stage test for progressive diabetic kidney disease.

Independent research has demonstrated that the soluble TNF receptors 1 and 2 are strong biomarkers of the disease and can be reliably used as diagnostic tests to predict end-stage renal disease up to ten years in advance.

Several new high-impact studies have been published corroborating original research by the Joslin Diabetes Center by underlining the strong association of elevated sTNFR1/2 levels with the subsequent development of advanced diabetic kidney disease in type 1 and 2 diabetic patients.

Such findings support and validate the use of EKF's sTNFR1 test, a microtitre plate, ELISA-based assay that uses monoclonal antibodies.

Julian Baines, chief executive officer of EKF Diagnostics, said: "Our sTNFR1 test has already been shown to add greatly to information provided by standard clinical criteria, allowing clinicians to pinpoint patients who need the most care as early as possible."

Earlier this month, the company strengthened its distribution network by launching a new Premium Partnership Program, while appointing Simona Carnielli as a European distribution manager.ADNFCR-8000103-ID-801724278-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.